Raymond James Financial
YMAB

Raymond James Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Raymond James Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,701
Closed -$34.7K – 6832
2025
Q2 		$34.7K Buy
+7,701
New +$34.6K ﹤0.01% 5335

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Raymond James Financial's YMAB Position: Q3 2025 in Review

Raymond James Financial sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 7,701 shares — an estimated $34.7K sold.

Raymond James Financial first reported a position in YMAB in Q2 2025 and held it in 1 quarter. The position peaked at $34.7K in Q2 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Raymond James Financial reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 7,701 Y-mAbs Therapeutics shares in Q3 2025, an estimated $34.7K.
  • Raymond James Financial first reported a position in Y-mAbs Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Y-mAbs Therapeutics position peaked at $34.7K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.